The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 06, 2016
Filed:
Feb. 25, 2014
Applicant:
Bayer Pharma Aktiengesellschaft, Berlin, DE;
Inventors:
Marcus Koppitz, Berlin, DE;
Ulrich Klar, Berlin, DE;
Antje Margret Wengner, Berlin, DE;
Roland Neuhaus, Berlin, DE;
Gerhard Siemeister, Berlin, DE;
Michael Brüning, Berlin, DE;
Assignee:
BAYER PHARMA AKTIENGESELLSCHAFT, Berlin, DE;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/4188 (2006.01); C07D 237/00 (2006.01); C07D 487/04 (2006.01); A61K 31/282 (2006.01); A61K 31/5025 (2006.01); A61K 31/52 (2006.01); A61K 31/573 (2006.01); A61K 31/675 (2006.01); A61K 31/69 (2006.01); A61K 31/704 (2006.01); A61K 31/7068 (2006.01); A61K 33/24 (2006.01); A61K 38/14 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); A61K 31/282 (2013.01); A61K 31/4188 (2013.01); A61K 31/5025 (2013.01); A61K 31/52 (2013.01); A61K 31/573 (2013.01); A61K 31/675 (2013.01); A61K 31/69 (2013.01); A61K 31/704 (2013.01); A61K 31/7068 (2013.01); A61K 33/24 (2013.01); A61K 38/14 (2013.01); A61K 39/3955 (2013.01); C07D 237/00 (2013.01); A61K 2039/505 (2013.01);
Abstract
The present invention relates to substituted imidazopyridazine compounds, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.